MCRB logo

Seres Therapeutics (MCRB)

Profile

Full Name

Seres Therapeutics, Inc.

Ticker Symbol

MCRB

Exchange

NASDAQ

Country

United States

IPO

June 26, 2015

Indexes

Not included

Employees

103

Key Details

Price

$0.46(-30.32%)

Market cap

Last Dividend

-

TTM Dividend yield

-

Annual revenue

-

Annual EPS

$0.00(+100.00% YoY)

PE ratio

-

Next earnings date

May 8, 2025

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price Performance

Price Range

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Shares Outstanding

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

EPS

Profit

Expenses

EBIT & EBITDA

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Liabilities

Debt

Equity & Capital

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

CAPEX

Free Cash Flow

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

ROA & ROE

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Analyst ratings

Recent major analysts updates

Mar 20, 25 Chardan Capital
Buy
Mar 14, 25 Goldman Sachs
Sell
Nov 14, 24 Canaccord Genuity
Buy
Nov 13, 24 Chardan Capital
Buy
Oct 24, 24 JP Morgan
Underweight
Sep 13, 24 Canaccord Genuity
Buy
Aug 14, 24 Chardan Capital
Buy
Aug 14, 24 Canaccord Genuity
Buy
Jun 7, 24 Oppenheimer
Perform
Jun 7, 24 Canaccord Genuity
Buy

Institutional Ownership

  • What is the ticker symbol for Seres Therapeutics?
  • Does Seres Therapeutics pay dividends?
  • What sector is Seres Therapeutics in?
  • What industry is Seres Therapeutics in?
  • What country is Seres Therapeutics based in?
  • When did Seres Therapeutics go public?
  • Is Seres Therapeutics in the S&P 500?
  • Is Seres Therapeutics in the NASDAQ 100?
  • Is Seres Therapeutics in the Dow Jones?
  • When was Seres Therapeutics's last earnings report?
  • When does Seres Therapeutics report earnings?
  • Should I buy Seres Therapeutics stock now?

What is the ticker symbol for Seres Therapeutics?

The ticker symbol for Seres Therapeutics is NASDAQ:MCRB

Does Seres Therapeutics pay dividends?

No, Seres Therapeutics does not pay dividends

What sector is Seres Therapeutics in?

Seres Therapeutics is in the Healthcare sector

What industry is Seres Therapeutics in?

Seres Therapeutics is in the Biotechnology industry

What country is Seres Therapeutics based in?

Seres Therapeutics is headquartered in United States

When did Seres Therapeutics go public?

Seres Therapeutics's initial public offering (IPO) was on June 26, 2015

Is Seres Therapeutics in the S&P 500?

No, Seres Therapeutics is not included in the S&P 500 index

Is Seres Therapeutics in the NASDAQ 100?

No, Seres Therapeutics is not included in the NASDAQ 100 index

Is Seres Therapeutics in the Dow Jones?

No, Seres Therapeutics is not included in the Dow Jones index

When was Seres Therapeutics's last earnings report?

Seres Therapeutics's most recent earnings report was on Mar 13, 2025

When does Seres Therapeutics report earnings?

The next expected earnings date for Seres Therapeutics is May 8, 2025

Should I buy Seres Therapeutics stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page